Here's Why Array Technologies, Inc. (ARRY) is a Strong Momentum Stock

Company Overview - Array Technologies, Inc. is a biopharmaceutical company based in Boulder, CO, focused on the discovery, development, and commercialization of targeted small molecule drugs for treating cancer and other high-burden diseases [12] - The company has one marketed combination therapy, Braftovi (encorafenib) plus Mektovi (binimetinib), approved for treating unresectable or metastatic melanoma with a BRAF V600E or V600K mutation [12] Investment Ratings - Array Technologies, Inc. currently holds a Zacks Rank of 3 (Hold) with a VGM Score of A [13] - The company has a Momentum Style Score of A, with shares increasing by 23.5% over the past four weeks [13] Earnings Estimates - For fiscal 2025, four analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate increasing by $0.05 to $0.68 per share [13] - Array Technologies boasts an average earnings surprise of +19.8% [13] Investment Considerations - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, Array Technologies should be on investors' short list [14]